Advanced Search
Contact | Corporate | Help

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Sponsors:
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • Multiple Myeloma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: DFRF4539A
Enrollment:
45

Additional information about NCT01432353.


SourceSolution © 2008-2012